1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Rabies - Drugs In Development, 2022, provides an overview of the Rabies (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, swallowing difficult, excitability, fever and convulsions. The predisposing factors include exposure to wildlife and exposure to other pets that may not be vaccinated.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Rabies - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Rabies (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Rabies (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rabies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 7, 3, 3, 12, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 6 and 2 molecules, respectively.
Rabies (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Rabies (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Rabies (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rabies (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rabies (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rabies (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rabies (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rabies (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Rabies - Overview
- Rabies - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Rabies - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Rabies - Companies Involved in Therapeutics Development
- Rabies - Drug Profiles
- Rabies - Dormant Projects
- Rabies - Discontinued Products
- Rabies - Product Development Milestones
- Featured News & Press Releases
- Jan 24, 2022: Chongqing Zhifei Biological Products Announcement on obtaining the summary report of phase III clinical trial of Lyophilized Human Rabies Vaccine (MRC-5 Cells)
- Jan 24, 2022: Kangtai Biology announces registration site verification notice of freeze-dried human rabies vaccine
- Jul 16, 2020: Biotec freeze-dried human rabies vaccine (serum-free Vero cells) obtained clinical trial approval
- Jun 30, 2020: China develops novel rabies vaccine
- Jan 07, 2020: CureVac announces positive results in low dose - 1 µg - Rabies vaccine clinical phase 1 study
- Sep 03, 2019: Zydus to launch novel biologic for rabies, Twinrab
- Jul 22, 2019: Yisheng Biopharma receives GMP certification from China NMPA for production of lyophilized rabies vaccine for preventive use
- Oct 23, 2018: CureVac announces first study participant enrolled in Phase I clinical trial testing prophylactic mRNA
- Oct 08, 2018: Yisheng Biopharma announces clearance from China FDA to proceed with PIKA rabies vaccine clinical study
- Jun 30, 2017: SYN023, Synermore’s human rabies immunoglobulin antibody drug received IND approval from CFDA for the Clinical Phase I trial study
- Jan 04, 2017: US FDA Grants Orphan Drug Designation to Yisheng Biopharma's PIKA Rabies Vaccine
- Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant
- Jul 31, 2015: SYN023, Synermore's human rabies immunoglobulin antibody drug submitted IND application to CFDA for the Clinical Phase I trial study
- May 31, 2015: SYN023, Synermore's human rabies immunoglobulin antibody drug received IND approval from FDA for the Clinical Phase I trial study
- Apr 30, 2015: SYN023, Synermore's human rabies immunoglobulin antibody drug submitted IND application to FDA for the Clinical Phase I trial study
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Rabies, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Companies, 2022 (Contd..2)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Rabies - Dormant Projects, 2022
- Rabies - Dormant Projects, 2022 (Contd..1)
- Rabies - Discontinued Products, 2022
- Number of Products under Development for Rabies, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AIM Vaccine Co Ltd
- Beijing Minhai Biotechnology Co Ltd
- Changchun Bcht Biotechnology Co Ltd
- Chengdu Institute of Biological Products Co Ltd
- Chengdu Rongsheng Pharmaceutical Co Ltd
- China Medical System Holdings Ltd
- Chongqing Zhifei Biological Products Co Ltd
- Clover Biopharmaceuticals Ltd
- CPL Biologicals Pvt Ltd
- Curevac NV
- Genrix (Shanghai) Biopharmaceutical Co Ltd
- Indian Immunologicals Ltd
- Jiangsu Kangrun Biological Technology Co Ltd
- Liaoning Cheng Da Biotechnology Co Ltd
- Mid-Atlantic BioTherapeutics, Inc.
- Molecular Targeting Technologies Inc
- Oita University Institute of Advanced Medicine Inc
- Prosetta Biosciences Inc
- Real Benefitspot Pharmaceutical Co Ltd
- Sanofi
- Shandong Yidu Biotechnology Co Ltd
- Shanghai Bovax Biotechnology Co Ltd
- Shanghai Qingsai Biotechnology Co Ltd
- Shanghai Rongsheng Biotech Co Ltd
- Shenzhen Weiguang Biological Products Co Ltd
- Synermore Biologics Co Ltd
- Trellis Bioscience Inc
- Vir Biotechnology Inc
- Yisheng Biopharma Co Ltd
- Zydus Lifesciences Ltd
